Last $4.49 USD
Change Today -0.06 / -1.32%
Volume 94.0K
HBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

harvard bioscience inc (HBIO) Snapshot

Open
$4.52
Previous Close
$4.55
Day High
$4.54
Day Low
$4.42
52 Week High
12/20/13 - $5.15
52 Week Low
04/24/13 - $3.50
Market Cap
143.5M
Average Volume 10 Days
117.9K
EPS TTM
$0.01
Shares Outstanding
31.9M
EX-Date
--
P/E TM
317.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARVARD BIOSCIENCE INC (HBIO)

Related News

No related news articles were found.

harvard bioscience inc (HBIO) Related Businessweek News

No Related Businessweek News Found

harvard bioscience inc (HBIO) Details

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets scientific instruments, systems, and lab consumables used in life science research. The company offers syringe pumps and peristaltic pumps primarily under the Harvard Apparatus and KD Scientific brands, as well as component pumping modules; and lab equipment and supplies comprising pipettes and pipette tips, gloves, gel electrophoresis and autoradiography products, thermal cycler accessories and reagents, general lab equipment and consumables, and tissue culture products primarily under the Denville Scientific, Hoefer, and Scie-Plas brands. It also provides molecular analysis products, such as spectrophotometers under the UltroSpec, NovaSpec, Libra, and BioDrop brands; microplate readers under the Asys Hitech and Anthos Labtec brands; and amino acid analyzers under the Biochrom brand. In addition, the company offers electroporation and electrofusion products comprising systems and generators, electrodes, and accessories under the Harvard Apparatus BTX brand; and cell electrophysiology products, such as equipment for patch clamps, amplifiers, bilayer workstations, temperature controllers, chambers, and accessories under the Warner Instrument brand. Further, it provides physiology products, which include a range of instruments and accessories for tissue, organ, and animal based lab research, ranging from surgical products, infusion systems, microdialysis instruments, behavior research products, isolated perfused organ and tissue bath systems, and research-based regenerative medicine products under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, and InBreath Bioreactor brands. It markets its products to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies through catalogs, distributors, direct sales force, and its Websites. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

345 Employees
Last Reported Date: 03/14/14
Founded in 1901

harvard bioscience inc (HBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $271.8K
Co-Founder and Director
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $54.8K
Vice President of Strategic Marketing and Bus...
Total Annual Compensation: $64.5K
Vice President of Global Sales
Total Annual Compensation: $34.0K
Compensation as of Fiscal Year 2013.

harvard bioscience inc (HBIO) Key Developments

Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality

Harvard Bioscience Inc. has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position. Mr. Aplin has more than 25 years experience in operations and supply chain management. He comes to Harvard Bioscience from Corning Incorporated, where he served as Operations/Plant Manager since 2012. Prior to Corning, he worked as Director of Operations at Becton, Dickinson and Company.

Harvard Bioscience, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Full Year of Fiscal 2014

Harvard Bioscience Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. Revenues for the three months ended December 31, 2013 were $27.9 million, a decrease of approximately $0.4 million, or 1.4% compared to revenues of $28.2 million for the three months ended December 31, 2012. Loss from continuing operations, as measured under U.S. generally accepted accounting principles (GAAP), was a $0.3 million loss, or $0.01 loss per share for the three months ended December 31, 2013 compared to income of $1.2 million or $0.04 per diluted share for the same period in 2012. The unfavorable year-to-year quarterly GAAP earnings comparison was due to a combination of a $2.1 million restructuring charge taken in the current quarter related to the Company's December 2013 restructuring plan and the costs incurred from the elimination of the position of Chief Operating Officer, lower revenues and higher costs associated with inventory write-offs. Income from continuing operations, on a non-GAAP basis, was $1.7 million or $0.05 per diluted share for the three months ended December 31, 2013 compared to $2.7 million or $0.09 per diluted share for the same period in 2012. The unfavorable year-to-year quarterly non-GAAP earnings comparison was due primarily to lower revenues and higher costs associated with inventory write-offs. Operating loss was $0.949 million against income of $2.138 million a year ago. Loss from continuing operations before income taxes was $1.268 million against income of $1.989 million a year ago. Net loss was $0.756 million or $0.02 diluted per share against income of $1.200 million or $0.04 diluted per share a year ago. Non-GAAP adjusted operating income was $2.706 million against $4.078 million a year ago. Non-GAAP adjusted income from continuing operations was $1.703 million or $0.05 diluted per share against $2.748 million or $0.09 diluted per share a year ago. Revenues for the year ended December 31, 2013 were $105.2 million, a decrease of $6.0 million, or 5.4%, compared to revenues of $111.2 million for the year ended December 31, 2012. Income from continuing operations, as measured under GAAP, was $0.7 million, or $0.02 per diluted share, for the year ended December 31, 2013 compared to $4.5 million, or $0.15 per diluted share, for the same period in 2012. The unfavorable year-to-year GAAP earnings comparison was due to a combination of a $2.1 million restructuring charge taken in the current quarter related to the company's December 2013 restructuring plan and the costs incurred from the elimination of the position of Chief Operating Officer, higher transaction costs associated with HART and lower revenues. Income from continuing operations, on a non-GAAP basis, was $7.1 million, or $0.22 per diluted share, for the year ended December 31, 2013 compared to $10.2 million, or $0.34 per diluted share, for the same period in 2012. The unfavorable year-to-year non-GAAP earnings comparison was due primarily to lower revenues. Operating income was $1.537 million against $7.830 million a year ago. Income from continuing operations before income taxes was $0.435 million against $6.892 million a year ago. Net loss was $1.830 million or $0.06 diluted per share against income of $2.370 million or $0.08 diluted per share a year ago. Net cash provided by operating activities was $4.060 million against $8.062 million a year ago. Non-GAAP adjusted operating income was $10.924 million against $14.919 million a year ago. Non-GAAP adjusted income from continuing operations was $7.062 million or $0.22 diluted per share against $10.220 million or $0.34 diluted per share a year ago. The company provided earnings guidance for the full year of fiscal 2014. GAAP diluted earnings per common share from continuing operations were $0.15 and non-GAAP adjusted diluted earnings per common share from continuing operations was $0.26.

Harvard Bioscience Mulls Acquisitions

Harvard Bioscience Inc. (NasdaqGM:HBIO) is looking for acquisitions. Jeffrey A. Duchemin, Chief Investment Officer, and President said, “2013 was a pivotal and exhilarating year for Harvard Bioscience. Following the spin-off of HART, we created a dedicated platform from which we expect to profitably grow our business. With our singular focus on our core business, our plans include expanding in Asia and other emerging markets, building stronger channel capabilities, reinvigorating product development, driving efficiencies through operations and improved cost structure, and implementing a new acquisition strategy.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HBIO:US $4.49 USD -0.06

HBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.70 USD -0.49
Bio-Rad Laboratories Inc $124.02 USD +0.02
Danaher Corp $73.38 USD -0.17
PerkinElmer Inc $44.54 USD +0.20
Thermo Fisher Scientific Inc $119.39 USD -0.96
View Industry Companies
 

Industry Analysis

HBIO

Industry Average

Valuation HBIO Industry Range
Price/Earnings 100.0x
Price/Sales 1.3x
Price/Book 1.5x
Price/Cash Flow 191.3x
TEV/Sales 0.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARVARD BIOSCIENCE INC, please visit www.harvardbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.